Direct bilirubin in clinical practice — Interpretation and haemolysis interference guidance reassessed

Clinical Biochemistry

Volumn 49, Issue 18, 2016, Pages 1351-1353

  Devgun, M S ^a   Richardson, C ^a  

^a WISHAW GENERAL HOSPITAL   (United Kingdom)

Author keywords

Direct bilirubin; Haemolysis; Hyperbilirubinaemia; Serum indices; Test interpretation

Indexed keywords

ALBUMIN; BILIRUBIN GLUCURONIDE; HEMOGLOBIN; TRIACYLGLYCEROL; VANADIC ACID; BILIRUBIN;

ADULT; ARTICLE; BLOOD ANALYSIS; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL PRACTICE; CONTROLLED STUDY; FEMALE; HEMOLYSIS; HEMOLYSIS ASSAY; HUMAN; HYPERBILIRUBINEMIA; INFANT; INTERMETHOD COMPARISON; MALE; MEASUREMENT ACCURACY; NEWBORN; PLEIOTROPY; PRIORITY JOURNAL; SERUM; BLOOD; REFERENCE VALUE;

BILIRUBIN; HUMANS; HYPERBILIRUBINEMIA; INFANT, NEWBORN; REFERENCE VALUES;

EID: 84999740162     PISSN: 00099120     EISSN: 18732933     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2016.09.005     Document Type: Article

References (16)

1. [1] Devgun, M.S., Chan, M.K., El-Nujumi, A.M., Abara, R., Armbruster, D., Adeli, K., Clinical decision limits for interpretation of direct bilirubin — a CALIPER study of healthy multiethnic children and case report reviews. Clin. Biochem. 48 (2015), 93–96.
2. [2] Lippi, G., Systematic assessment of the hemolysis index: pros and cons. Adv. Clin. Chem., June 2015, 10.1016/bs.acc.2015.05.002.
3. [3] Fevery, J., Bilirubin in clinical practice: a review. Liver Int., 2008, 592–605, 10.1111/j.1478-3231.2008.01716.x.
4. [4] Ahlfors, C.E., Wennberg, R.P., Ostrow, J.D., Tiribelli, C., Unbound (free) bilirubin: improving the paradigm for evaluating neonatal jaundice. Clin. Chem. 55 (2009), 1288–1299.
5. [5] UKNEQAS, Report no 215. http://www.birminghamquality.org.uk (Accessed 19/01/2016).
6. [6] Lippi, G., Blanckaert, N., Bonini, P., Green, S., Kitchen, S., Palicka, V., Vassault, A.J., Plebani, M., Haemolysis: an overview of the leading cause of unsuitable specimens in clinical laboratories. Clin. Chem. Lab. Med. 46 (2008), 764–772.
7. [7] Roche Diagnostics GmbH, Mannheim, Germany. www.roche.com. Accessed 19/01/2016.
8. [8] Saibaba, K.S.S., Bhaskar, M.V., Rao, P.V.L.N.S., Ramana, G.V., Dakshinamurty, K.V., Interferences in clinical chemistry analysis. Indian J. Clin. Biochem. 13 (1998), 55–62.
9. [9] Serum Index Gen.2, 010572179190c701v4.0, 2014–02, cobas c, Roche Diagnostics, Gmbh, Mannheim, Germany.
10. [10] Direct Bilirubin L-Type. Wako Chemicals, GmbH, Neuss, Germany. www.wako-chemicals.de. Accessed19/01/2016.
11. [11] Kroll, M.H., Elin, R.J., Interference with clinical laboratory analyses. Clin. Chem. 40 (1994), 1996–2005.
12. [12] Dolci, A., Panteghini, M., Harmonization of automated hemolysis index assessment and use: is it possible?. Clin. Chim. Acta 432 (2014), 38–43.
13. [13] Devgun, M.S., Delay in centrifugation and measurement of serum constituents in normal subjects. Clin. Physiol. Biochem. 7 (1989), 189–197.
14. [14] Zhang Ji, J., Meng, Q.H., Evaluation of the interference of hemoglobin, bilirubin, and lipids on Roche Cobas 6000 assays. Clin. Chim. Acta 412 (2011), 1550–1553.
15. [15] Penhaker, M., Kasik, V., Hrvolova, B., Advanced bilirubin measurement by a photometric method. Elektron. Elektrotech. 19 (2013), 47–50.
16. [16] Devgun, M.S., El-Nujumi, A.M., O'Dowd, G.J., Barbu, V., Poupon, R., Novel mutations in the Dubin–Johnson syndrome gene ABCC2/MRP2 and associated biochemical changes. Ann. Clin. Biochem. 49 (2012), 609–612.